Perspectives on the development of neutralizing antibodies against SARS-CoV-2

@article{Ho2020PerspectivesOT,
  title={Perspectives on the development of neutralizing antibodies against SARS-CoV-2},
  author={Mitchell Ho},
  journal={Antibody Therapeutics},
  year={2020},
  volume={3},
  pages={109 - 114}
}
  • Mitchell Ho
  • Published 2020
  • Biology, Medicine
  • Antibody Therapeutics
  • Abstract SARS-CoV-2 gains entry to human cells through its spike (S) protein binding to angiotensin-converting enzyme 2 (ACE2). Therefore, the receptor binding domain (RBD) of the S protein is the primary target for neutralizing antibodies. Selection of broad-neutralizing antibodies against SARS-CoV-2 and SARS-CoV is attractive and might be useful for treating not only COVID-19 but also future SARS-related CoV infections. Broad-neutralizing antibodies, such as 47D11, S309, and VHH-72, have been… CONTINUE READING

    Citations

    Publications citing this paper.

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 39 REFERENCES

    The proximal origin of SARS-CoV-2

    VIEW 4 EXCERPTS
    HIGHLY INFLUENTIAL

    Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

    VIEW 4 EXCERPTS
    HIGHLY INFLUENTIAL

    A cold-blooded view of adaptive immunity

    VIEW 1 EXCERPT